Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant
Abstract
The emergence of rapid-acting antidepressants such as ketamine has motivated studies aiming to reveal the molecular mechanism of the ketamine antidepressant effect and to enable the clinical application of rapid-acting antidepressants. Here, we provide an overview of studies addressing the antidepressant effects of ketamine in depressed patients and animal models of depression and we compare the reduction of depressive symptoms in humans with the reduction in immobility time in the forced swim test in rodents after acute ketamine treatment. We also discuss different theories and potential biochemical pathways involved in the rapid antidepressant response to ketamine including the modulation of glutamatergic neurotransmission and intracellular hub-kinase activation. Finally, we summarize recent brain-region specific studies and we suggest that the activation of the ventral hippocampusmedial prefrontal cortexdorsal raphae nuclei (vHC-mPFC-DRN) neuronal pathway may mediate the antidepress...ant effect of ketamine. Although substantial progress has been made, further brain-region specific animal studies and longitudinal clinical trials are necessary for the understanding and successful application of novel rapid-acting antidepressants. Drug Dev Res 77 : 414-422, 2016.
Source:
Drug Development Research, 2016, 77, 7, 414-422Publisher:
- Wiley, Hoboken
Funding / projects:
- Biomarkers of organ damage and dysfunction (RS-175036)
DOI: 10.1002/ddr.21335
ISSN: 0272-4391
PubMed: 27546787
WoS: 000387856500011
Scopus: 2-s2.0-84994112380
Collections
Institution/Community
PharmacyTY - JOUR AU - Pešić, Vesna AU - Petrović, Jelena AU - Jukić, Marin PY - 2016 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2625 AB - The emergence of rapid-acting antidepressants such as ketamine has motivated studies aiming to reveal the molecular mechanism of the ketamine antidepressant effect and to enable the clinical application of rapid-acting antidepressants. Here, we provide an overview of studies addressing the antidepressant effects of ketamine in depressed patients and animal models of depression and we compare the reduction of depressive symptoms in humans with the reduction in immobility time in the forced swim test in rodents after acute ketamine treatment. We also discuss different theories and potential biochemical pathways involved in the rapid antidepressant response to ketamine including the modulation of glutamatergic neurotransmission and intracellular hub-kinase activation. Finally, we summarize recent brain-region specific studies and we suggest that the activation of the ventral hippocampusmedial prefrontal cortexdorsal raphae nuclei (vHC-mPFC-DRN) neuronal pathway may mediate the antidepressant effect of ketamine. Although substantial progress has been made, further brain-region specific animal studies and longitudinal clinical trials are necessary for the understanding and successful application of novel rapid-acting antidepressants. Drug Dev Res 77 : 414-422, 2016. PB - Wiley, Hoboken T2 - Drug Development Research T1 - Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant VL - 77 IS - 7 SP - 414 EP - 422 DO - 10.1002/ddr.21335 ER -
@article{ author = "Pešić, Vesna and Petrović, Jelena and Jukić, Marin", year = "2016", abstract = "The emergence of rapid-acting antidepressants such as ketamine has motivated studies aiming to reveal the molecular mechanism of the ketamine antidepressant effect and to enable the clinical application of rapid-acting antidepressants. Here, we provide an overview of studies addressing the antidepressant effects of ketamine in depressed patients and animal models of depression and we compare the reduction of depressive symptoms in humans with the reduction in immobility time in the forced swim test in rodents after acute ketamine treatment. We also discuss different theories and potential biochemical pathways involved in the rapid antidepressant response to ketamine including the modulation of glutamatergic neurotransmission and intracellular hub-kinase activation. Finally, we summarize recent brain-region specific studies and we suggest that the activation of the ventral hippocampusmedial prefrontal cortexdorsal raphae nuclei (vHC-mPFC-DRN) neuronal pathway may mediate the antidepressant effect of ketamine. Although substantial progress has been made, further brain-region specific animal studies and longitudinal clinical trials are necessary for the understanding and successful application of novel rapid-acting antidepressants. Drug Dev Res 77 : 414-422, 2016.", publisher = "Wiley, Hoboken", journal = "Drug Development Research", title = "Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant", volume = "77", number = "7", pages = "414-422", doi = "10.1002/ddr.21335" }
Pešić, V., Petrović, J.,& Jukić, M.. (2016). Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant. in Drug Development Research Wiley, Hoboken., 77(7), 414-422. https://doi.org/10.1002/ddr.21335
Pešić V, Petrović J, Jukić M. Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant. in Drug Development Research. 2016;77(7):414-422. doi:10.1002/ddr.21335 .
Pešić, Vesna, Petrović, Jelena, Jukić, Marin, "Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant" in Drug Development Research, 77, no. 7 (2016):414-422, https://doi.org/10.1002/ddr.21335 . .